MCID: BRS099
MIFTS: 63

Breast Ductal Carcinoma

Categories: Cancer diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Breast Ductal Carcinoma

MalaCards integrated aliases for Breast Ductal Carcinoma:

Name: Breast Ductal Carcinoma 11 14
Ductal Breast Carcinoma 53 5 71
Ductal Carcinoma 71 75
Mammary Ductal Carcinoma 71
Carcinoma, Ductal 43
Duct Carcinoma 11

Classifications:



External Ids:

Disease Ontology 11 DOID:3007
MeSH 43 D044584
SNOMED-CT 68 82711006
UMLS 71 C0021367 C1176475 C1527349

Summaries for Breast Ductal Carcinoma

Disease Ontology: 11 A breast carcinoma that derives from the lining of milk ducts.

MalaCards based summary: Breast Ductal Carcinoma, also known as ductal breast carcinoma, is related to bile duct cancer and intrahepatic cholangiocarcinoma. An important gene associated with Breast Ductal Carcinoma is RAD54L (RAD54 Like), and among its related pathways/superpathways are Signal Transduction and ERK Signaling. The drugs Ropivacaine and Ondansetron have been mentioned in the context of this disorder. Affiliated tissues include breast, salivary gland and lymph node, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and Increased cell death in HCT116 cells

Wikipedia: 75 Ductal carcinoma is a type of tumor that primarily presents in the ducts of a... more...

Related Diseases for Breast Ductal Carcinoma

Diseases related to Breast Ductal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 866)
# Related Disease Score Top Affiliating Genes
1 bile duct cancer 32.8 TP53 ERBB2 EGFR CTNNB1 CDH1 CCND1
2 intrahepatic cholangiocarcinoma 32.4 TP53 ERBB2 EGFR CTNNB1
3 breast cystic hypersecretory carcinoma 32.3 PGR ESR1 ERBB2
4 sebaceous breast carcinoma 32.3 PIP ERBB2
5 bile duct adenocarcinoma 32.1 TP53 EGFR CTNNB1 CDH1
6 cholangiocarcinoma 32.1 TP53 TFF1 KRT8 ERBB2 EGFR CTNNB1
7 ductal carcinoma in situ 31.7 TP53 PIP PGR KRT8 ESR1 ERBB2
8 pleomorphic adenoma 31.5 TP53 ERBB2 CTNNB1
9 breast cancer 31.3 ZFAS1 VEGFD TP53 TFF1 RAD54L PIP
10 adenoma 31.3 TP53 MKI67 CTNNB1 CDH1 CCND1 BCL2
11 adenocarcinoma 31.2 VEGFD TP53 ERBB2 EGFR CTNNB1 CDH1
12 salivary gland carcinoma 31.2 TP53 PIP ERBB2 EGFR
13 breast malignant phyllodes tumor 31.1 TP53 PGR ESR1 ERBB2 EGFR
14 transitional cell carcinoma 31.0 TP53 NME1 MKI67 ERBB2 EGFR CDH1
15 papillary adenocarcinoma 31.0 TP53 PIP NME1 ERBB2 BRCA1
16 pleomorphic adenoma carcinoma 31.0 TP53 ERBB2
17 cystadenocarcinoma 31.0 TP53 PGR BRCA1 BCL2
18 tubular adenocarcinoma 31.0 PGR ESR1 ERBB2 CTSD CTNNB1 CDH1
19 mucoepidermoid carcinoma 31.0 KRT8 EGFR CDH3 CDH1
20 renal cell carcinoma, papillary, 1 30.9 TP53 ERBB2 EGFR CDH1
21 sporadic breast cancer 30.8 TP53 PGR ESR1 ERBB2 BRCA1
22 comedo carcinoma 30.8 TP53 PGR ESR1 ERBB2
23 microglandular adenosis 30.8 PIP PGR ESR1 ERBB2 CTSD
24 leiomyosarcoma 30.8 TP53 PGR ESR1 CCND1 BRCA1 BCL2
25 cholecystitis 30.7 TP53 TFF1 EGFR CDH1
26 papillary carcinoma 30.7 NME1 MKI67 ESR1 ERBB2 CDH1
27 inherited cancer-predisposing syndrome 30.7 TP53 EGFR CDH1 BRCA1
28 bap1 tumor predisposition syndrome 30.7 TP53 EGFR CDH1 BRCA1
29 thyroid gland follicular carcinoma 30.7 TP53 CTNNB1 CDH1 CCND1
30 leukemia, chronic lymphocytic 30.7 TP53 ERBB2 EGFR CTNNB1 CCND1 BCL2
31 mucinous adenocarcinoma 30.7 TP53 ERBB2 EGFR CTNNB1
32 hereditary breast cancer 30.7 RAD54L CDH1 BRCA1
33 skin squamous cell carcinoma 30.7 TP53 ERBB2 EGFR CTNNB1 CDH1 CCND1
34 melanoma 30.6 TP53 NME1 MKI67 CTNNB1 CDH3 CDH1
35 diffuse gastric and lobular breast cancer syndrome 30.6 TP53 ERBB2 CTNNB1 CDH1 BRCA1
36 hypertrophy of breast 30.6 TP53 PGR ESR1 ERBB2 EGFR BRCA1
37 gallbladder disease 30.6 TP53 ERBB2 EGFR CTNNB1 CDH1 CCND1
38 breast adenoid cystic carcinoma 30.6 PGR ESR1 ERBB2
39 vulva cancer 30.6 TP53 PIP ERBB2 EGFR CCND1
40 hereditary breast ovarian cancer syndrome 30.6 TP53 RAD54L PGR ESR1 ERBB2 EGFR
41 breast metaplastic carcinoma 30.6 TP53 PGR ESR1 ERBB2
42 mammary paget's disease 30.6 PIP PGR ESR1 ERBB2
43 carcinosarcoma 30.6 TP53 PGR ERBB2 EGFR CTNNB1 CDH1
44 breast papillary carcinoma 30.5 PIP PGR ESR1 ERBB2
45 linitis plastica 30.5 PIP PGR ERBB2 CDH1
46 benign breast phyllodes tumor 30.5 PGR MKI67 ESR1
47 neuroendocrine carcinoma 30.5 PGR ESR1 CDH1
48 gynecomastia 30.5 PGR ESR1 ERBB2
49 esophagus squamous cell carcinoma 30.5 EGFR CTNNB1 CCND1
50 squamous cell carcinoma 30.5 TP53 NME1 MKI67 ERBB2 EGFR CTNNB1

Graphical network of the top 20 diseases related to Breast Ductal Carcinoma:



Diseases related to Breast Ductal Carcinoma

Symptoms & Phenotypes for Breast Ductal Carcinoma

GenomeRNAi Phenotypes related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.35 CCND1 ESR1 MKI67 PIP VEGFD
2 Increased cell death in HCT116 cells GR00103-A-0 8.85 CTNNB1
3 Decreased viability in pancreas lineage GR00235-A 8.8 CCND1 PGR TP53

MGI Mouse Phenotypes related to Breast Ductal Carcinoma:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.41 BCL2 BRCA1 CCND1 CDH1 CTNNB1 EGFR
2 homeostasis/metabolism MP:0005376 10.41 BCL2 BRCA1 CCND1 CDH1 CTNNB1 CTSD
3 growth/size/body region MP:0005378 10.34 BCL2 BRCA1 CCND1 CDH1 CTNNB1 CTSD
4 endocrine/exocrine gland MP:0005379 10.32 BCL2 BRCA1 CCND1 CDH1 CDH3 CTNNB1
5 normal MP:0002873 10.3 BRCA1 CCND1 CDH1 CTNNB1 EGFR ERBB2
6 digestive/alimentary MP:0005381 10.25 BCL2 BRCA1 CCND1 CDH1 CTNNB1 CTSD
7 cellular MP:0005384 10.22 BCL2 BRCA1 CCND1 CDH1 CTNNB1 CTSD
8 immune system MP:0005387 10.2 BCL2 BRCA1 CCND1 CDH1 CTNNB1 CTSD
9 cardiovascular system MP:0005385 10.18 BCL2 BRCA1 CCND1 CDH1 CTNNB1 EGFR
10 embryo MP:0005380 10.16 BCL2 BRCA1 CDH1 CTNNB1 EGFR ERBB2
11 muscle MP:0005369 10.14 BCL2 BRCA1 CTNNB1 EGFR ERBB2 ESR1
12 no phenotypic analysis MP:0003012 10.09 CDH1 CTNNB1 EGFR ESR1 MKI67 PGR
13 limbs/digits/tail MP:0005371 10.07 BRCA1 CTNNB1 EGFR ERBB2 ESR1 PGR
14 reproductive system MP:0005389 10.03 BCL2 BRCA1 CCND1 CDH1 CTNNB1 EGFR
15 hematopoietic system MP:0005397 9.97 BCL2 BRCA1 CCND1 CTNNB1 CTSD EGFR
16 mortality/aging MP:0010768 9.83 BCL2 BRCA1 CCND1 CDH1 CTNNB1 CTSD
17 integument MP:0010771 9.44 BCL2 BRCA1 CCND1 CDH1 CDH3 CTNNB1

Drugs & Therapeutics for Breast Ductal Carcinoma

Drugs for Breast Ductal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 231)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
2
Ondansetron Approved, Withdrawn Phase 4 99614-02-5 4595
3
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
4
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
5 Dsuvia Phase 4
6 Anesthetics, Intravenous Phase 4
7 Anesthetics, General Phase 4
8 Analgesics, Opioid Phase 4
9 Hormones Phase 4
10 Estrogens Phase 4
11 Estrogen Receptor Antagonists Phase 4
12 Estrogen Antagonists Phase 4
13 Hormone Antagonists Phase 4
14 Aromatase Inhibitors Phase 4
15
Goserelin Approved Phase 2, Phase 3 65807-02-5 5311128 47725
16
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
17
Leuprolide Approved, Investigational Phase 2, Phase 3 53714-56-0 657181
18
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
19
Tamoxifen Approved Phase 3 10540-29-1, 54965-24-1 2733526
20
Lapatinib Approved, Investigational Phase 2, Phase 3 231277-92-2, 388082-78-8 208908
21
Medroxyprogesterone acetate Approved, Investigational Phase 3 520-85-4, 71-58-9 6279 10631
22
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
23
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3 135329020
24
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
25
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
26
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
27
Epirubicin Approved Phase 3 56420-45-2 41867
28
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
29
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
30
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
31
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
32
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
33
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
34
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
35
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
36
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
37 Neurotransmitter Agents Phase 3
38 Parasympatholytics Phase 3
39 Mandelic Acids Phase 3
40 Muscarinic Antagonists Phase 3
41 Cholinergic Antagonists Phase 3
42 Cholinergic Agents Phase 3
43 Antineoplastic Agents, Hormonal Phase 3
44 Estrogen Receptor Modulators Phase 3
45 Selective Estrogen Receptor Modulators Phase 3
46 Antirheumatic Agents Phase 3
47 Estrogens, Conjugated (USP) Phase 3
48 Contraceptives, Oral, Hormonal Phase 3
49 Contraceptive Agents, Male Phase 3
50 Liposomal doxorubicin Phase 3

Interventional clinical trials:

(show top 50) (show all 270)
# Name Status NCT ID Phase Drugs
1 The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery. A Double Blind, Randomised, Placebo Controlled Trial. Unknown status NCT04248179 Phase 4 Ropivacaine injection;Saline 0.9%;Sufentanil and PONV prophylaxis
2 Electronic Xoft Intersociety Brachytherapy Trial Completed NCT00742222 Phase 4
3 A Clinical Evaluation Of Adipose Derived Regenerative Cells In The Treatment Of Patients With BrEast Deformities Post Segmental Breast ResecTion (Lumpectomy) With Or Without Radiation ThErapy. A Phase IV Post Market Study. Completed NCT00616135 Phase 4
4 Effect of Huaier Granule on Postoperative Adjuvant Treatment for High-risk Early-stage Triple-negative Invasive Ductal Carcinoma: a Prospective, Multicenter, Randomized, Controlled, Open-label Study Recruiting NCT04790305 Phase 4 Huaier Granule
5 Association of HSD3B1 Genotype With Response to Preoperative Letrozole Therapy Among Postmenopausal Women With Estrogen-Receptor Positive (ER+) HER2/Neu-Negative (HER2-) Invasive Carcinomas of the Breast Recruiting NCT05183828 Phase 4 Letrozole
6 Interstitial Brachytherapy Alone Versus External Beam Radiation Therapy After Breast Conserving Surgery for Low-risk Invasive Carcinoma and Low-risk Ductal Carcinoma in Situ (DCIS) of the Female Breast Unknown status NCT00402519 Phase 3
7 A Randomized Phase III Study to Investigate the Efficacy and Safety of Docetaxel + Capecitabine vs. Vinorelbine + Capecitabine Followed by Capecitabine Alone as 1st Therapy on Locally Advanced and Metastatic Breast Cancer Patients. Unknown status NCT01126138 Phase 3 Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine;Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine
8 A Prospective, Randomized, Open-label Comparison of Preoperative Weekly Paclitaxel and Cisplatin With or Without Endocrine Therapy in Patients With Operable Hormone Receptor Positive and Triple Negative Locally Advanced Breast Cancer Unknown status NCT02221999 Phase 2, Phase 3 Paclitaxel;Cisplatin;Gonadotropin-releasing hormone agonist;Letrozole
9 A Randomized Phase III Trial of Comparing Combination Administration of Paclitaxel and Cisplatin Versus CEF as Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy Unknown status NCT02879513 Phase 3 Paclitaxel;Cisplatin;Epirubicin;Cyclophosphamide;5-fluoruracil
10 A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes Completed NCT02961790 Phase 3 Oxybutynin Chloride
11 A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
12 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
13 A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
14 Evaluation of a New Intraoperative Gamma Camera for the Sentinel Lymph Node Procedure in Breast Cancer Completed NCT00757302 Phase 3
15 Conservative Surgery With or Without Axillary Lymphnode Removal in Treating Women With T1N0 Breast Cancer Completed NCT01508546 Phase 3
16 A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Completed NCT02125344 Phase 3 non-pegylated liposomal doxorubicin;Carboplatin;Paclitaxel;Epirubicin;Cyclophosphamide;Pertuzumab;Trastuzumab;Ferric carboxymaltose
17 CirCe01 Study: Evaluation of the Use of Circulating Tumour Cells to Guide Chemotherapy From the 3rd Line of Chemotherapy for Metastatic Breast Cancer Completed NCT01349842 Phase 3
18 A Randomized Phase III Trial Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto) Completed NCT01583426 Phase 3 nab-Paclitaxel;Paclitaxel
19 A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
20 Phase III Trial of Tamoxifen Alone vs. Tamoxifen Plus Radiation Therapy for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast Completed NCT00003857 Phase 3 tamoxifen citrate
21 Optimizing Preventative Adjuvant Linac-Based Radiation: The OPAL Trial a Phase II/III Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer Recruiting NCT03077841 Phase 2, Phase 3
22 Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk and Estrogen Receptor-Positive Ductal Carcinoma in Situ of Breast: an International Open-label Randomized Non-inferiority Trial Recruiting NCT04046159 Phase 3 Low-dose tamoxifen
23 Phase 3 Study of Weekly Paclitaxel in Combination With Cisplatin as Adjuvant Chemotherapy for Early Stage Human Epidermal Growth Factor Receptor-2 (HER2) Negative Breast Cancer in High-risk Women Recruiting NCT03201861 Phase 3 Paclitaxel, Cisplatin;EC to docetaxel or paclitaxel
24 Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women Active, not recruiting NCT01905046 Phase 3 metformin hydrochloride
25 Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin Active, not recruiting NCT02620280 Phase 3 Carboplatin;Abraxane;MPDL3280A;Anthra
26 Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study Active, not recruiting NCT01953588 Phase 3 fulvestrant;anastrozole
27 RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction Active, not recruiting NCT03414970 Phase 3
28 A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy Active, not recruiting NCT00769379 Phase 3
29 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer Active, not recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
30 A Randomised Phase III Study of Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
31 A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Active, not recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
32 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Terminated NCT02715804 Phase 3 Placebo;nab-Paclitaxel;Gemcitabine
33 Intra-mammary Distribution of Transdermal Telapristone Versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy Unknown status NCT02314156 Phase 2 Telapristone Acetate
34 A Phase II Randomized Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ Unknown status NCT00669747 Phase 2 Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
35 Randomised Trial Testing Observation (No Radiotherapy) Against Radiotherapy In Women With Low-Risk Completely Excised ER Positive Ductal Carcinoma In Situ (DCIS) Of The Breast On Adjuvant Endocrine Therapy Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
36 Resectable Pancreatic Adenocarcinoma Neo-Adjuvant FOLF(IRIN)OX-based CHEmotherapy - A Multicenter, Randomised Phase II Trial (PANACHE01-PRODIGE48 Study) Unknown status NCT02959879 Phase 2 FOLFOX neoadjuvant chemotherapy;FOLFIRINOX neoadjuvant chemotherapy;Standard adjuvant chemotherapy;adjuvant chemotherapy
37 A Phase II, Open-label, Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma Unknown status NCT01016002 Phase 2 Temoporfin
38 A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease Completed NCT01849250 Phase 2 Docosahexaenoic Acid
39 A Randomized, Placebo-Controlled Phase II Clinical Trial of Omega-3 PUFA Dietary Supplementation in Patients With Stage I-III Breast Carcinoma Completed NCT01869764 Phase 2 omega-3 fatty acid
40 Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
41 Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining FSH and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer Completed NCT03947151 Phase 2 Degarelix injection(s)
42 A Randomized Trial to Explore the Effect of Oral Omega 3 Fatty Acids on Atrophic Vaginitis in Postmenopausal Breast Cancer Survivors Completed NCT02150525 Phase 2
43 Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast. Completed NCT03002766 Phase 2
44 Randomized Phase II Biomarker Pilot Trial of Fluvastatin Use in Women With Ductal Carcinoma in Situ (DCIS) or Stage I Breast Cancer Completed NCT00416403 Phase 2 fluvastatin sodium
45 Sulforaphane: A Dietary Histone Deacetylase (HDAC) Inhibitor in Ductal Carcinoma in Situ (DCIS) Completed NCT00843167 Phase 2
46 MammoSite Radiation Therapy System (RTS) as the Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ (DCIS) Completed NCT00586326 Phase 2
47 Primary Hormonal Therapy for Ductal Carcinoma in Situ: Exploration of a Novel Approach to the Clinical Management of Noninvasive Breast Cancer Completed NCT00290745 Phase 1, Phase 2 letrozole;tamoxifen citrate
48 A Multicenter, Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) in Subjects With Advanced or Unresectable Pancreatic Ductal Carcinoma Whose Tumors Have Progressed Following Prior Treatment With Gemcitabine and Fluoropyrimidine-Based Chemotherapy Completed NCT01580397 Phase 2 INNO-206
49 Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS) Completed NCT01439711 Phase 2 letrozole
50 Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial Completed NCT01023477 Phase 1, Phase 2 Chloroquine Standard Dose (500mg/week);Chloroquine Low Dose (250mg/week)

Search NIH Clinical Center for Breast Ductal Carcinoma

Cochrane evidence based reviews: carcinoma, ductal

Genetic Tests for Breast Ductal Carcinoma

Anatomical Context for Breast Ductal Carcinoma

Organs/tissues related to Breast Ductal Carcinoma:

MalaCards : Breast, Salivary Gland, Lymph Node, Liver, Pancreas, Kidney, Prostate

Publications for Breast Ductal Carcinoma

Articles related to Breast Ductal Carcinoma:

(show top 50) (show all 4631)
# Title Authors PMID Year
1
Mutations in the RAD54 recombination gene in primary cancers. 5
10362365 1999
2
Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression. 53 62
20043090 2010
3
E-cadherin expression in estrogen receptor-positive and negative breast carcinomas of postmenopausal women. 53 62
20349789 2010
4
Interpretation of Pin-1 and VEGF-C expression in breast infiltrating duct carcinoma. 53 62
19885590 2009
5
A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day & 21 days after first cycle of chemotherapy in carcinoma of breast: a prospective non-randomized observational study. 53 62
19331661 2009
6
Interobserver variability and aberrant E-cadherin immunostaining of lobular neoplasia and infiltrating lobular carcinoma. 53 62
18587329 2008
7
[Relationship of ezrin protein expression to the carcinogenesis and prognosis of infitrating breast ductal carcinoma]. 53 62
18788632 2008
8
[Clinicopathologic significance of chromosome 17 polysomy in breast cancer]. 53 62
18681318 2008
9
Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. 53 62
17563907 2007
10
P63 and cytokeratin8/18 expression in breast, atypical ductal hyperplasia, ductal carcinoma in situ and invasive duct carcinoma. 53 62
19190693 2007
11
A mutation in the 5' untranslated region of the BRCA1 gene in sporadic breast cancer causes downregulation of translation efficiency. 53 62
17697535 2007
12
Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer. 53 62
17708365 2007
13
Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. 53 62
17599361 2007
14
Identification of a basal-like subtype of breast ductal carcinoma in situ. 53 62
17234468 2007
15
An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. 53 62
17244359 2007
16
Expression of nm23, MMP-2, TIMP-2 in breast neoplasm in Zhengzhou Center Hospital, China. 53 62
17642161 2007
17
CD44 expression and axillary lymph node metastasis in infiltrating ductal carcinoma of the breast. 53 62
18376796 2006
18
E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. 53 62
16791476 2006
19
Smad4-expression is decreased in breast cancer tissues: a retrospective study. 53 62
16438724 2006
20
Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas. 53 62
16080559 2005
21
Localisation of COX-2 protein is different in breast ductal carcinoma and adjacent non-tumour ductal epithelium. 53 62
16131446 2005
22
Transient transfection of epidermal growth factor receptor gene into MCF7 breast ductal carcinoma cell line. 53 62
15584089 2005
23
PPARgamma expression in breast cancer: clinical value and correlation with ERbeta. 53 62
15656884 2005
24
Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. 53 62
15649255 2005
25
The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma. 53 62
15850004 2005
26
Alterations of p53, Bcl-2, and hMSH2 protein expression in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas in the upper Egypt. 53 62
15467428 2004
27
Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis. 53 62
14736826 2004
28
Immunohistochemical status of p53, MDM2, bcl2, bax, and ER in invasive ductal breast carcinoma in Tunisian patients. 53 62
15033823 2003
29
Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma. 53 62
12883688 2003
30
Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. 53 62
12670886 2003
31
The epithelial-specific ETS transcription factor ESX/ESE-1/Elf-3 modulates breast cancer-associated gene expression. 53 62
12713734 2003
32
Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. 53 62
12527916 2003
33
Cell proliferation, nuclear ploidy, and EGFr and HER2/neu tyrosine kinase oncoproteins in infiltrating ductal breast carcinoma. 53 62
12419588 2002
34
Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer. 53 62
12168049 2002
35
The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer. 53 62
12148568 2002
36
p63 expression in normal, hyperplastic and malignant breast tissues. 53 62
12185332 2002
37
p53 gene alteration and protein expression in Iranian women with infiltrative ductal breast carcinoma. 53 62
11410327 2001
38
pS2 expression in infiltrating ductal carcinoma of the breast correlates with oestrogen receptor positivity but not with histological grade and lymph node status. 53 62
11523925 2001
39
The prognostic significance of P-cadherin in infiltrating ductal breast carcinoma. 53 62
11454996 2001
40
Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. 53 62
11169147 2001
41
Salivary duct carcinoma--a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. 53 62
11569926 2001
42
Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. 53 62
10941333 2000
43
Adrenocorticotropic hormone and growth factor receptors in breast cancer. 53 62
11215308 2000
44
Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: a pathway to metastatic progression in human breast cancer. 53 62
10754491 2000
45
Cyclin D1 overexpression in a model of human breast premalignancy: preferential stimulation of anchorage-independent but not anchorage-dependent growth is associated with increased cdk2 activity. 53 62
10752677 2000
46
Expression of glycodelin in human breast and breast cancer. 53 62
10597188 1999
47
A comparison of the pattern of cathepsin-D expression in fibroadenoma, fibrocystic disease, preinvasive and invasive ductal breast carcinoma. 53 62
10503271 1999
48
Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast. 53 62
10641149 1999
49
[Immunohistochemical tumor markers in infiltrating ductal breast carcinoma]. 53 62
10030093 1998
50
p53 protein expression in benign and malignant breast lesions. 53 62
9684577 1998

Variations for Breast Ductal Carcinoma

ClinVar genetic disease variations for Breast Ductal Carcinoma:

5 (show top 50) (show all 257)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 RAD54L NM_003579.4(RAD54L):c.973G>A (p.Gly325Arg) SNV Pathogenic
6193 rs121908690 GRCh37: 1:46733212-46733212
GRCh38: 1:46267540-46267540
2 overlap with 3 genes GRCh37/hg19 1p31.3(chr1:67327908-67519596)x3 CN GAIN Uncertain Significance
221411 GRCh37: 1:67327908-67519596
GRCh38:
3 overlap with 9 genes GRCh37/hg19 16q11.2-12.1(chr16:46615804-47345238)x1 CN LOSS Uncertain Significance
221520 GRCh37: 16:46615804-47345238
GRCh38:
4 overlap with 32 genes chr19:36674305-38652962 complex variant COMPLEX Uncertain Significance
221351 GRCh37: 19:36674305-38652962
GRCh38:
5 overlap with 2 genes GRCh37/hg19 6p22.1(chr6:30029374-30036983)x3 CN GAIN Uncertain Significance
221454 GRCh37: 6:30029374-30036983
GRCh38:
6 overlap with 13 genes GRCh37/hg19 17p13.1(chr17:8017865-8135384)x3 CN GAIN Uncertain Significance
221394 GRCh37: 17:8017865-8135384
GRCh38:
7 HTRA2 NM_013247.5(HTRA2):c.695T>A (p.Leu232Gln) SNV Uncertain Significance
221314 rs869025234 GRCh37: 2:74757932-74757932
GRCh38: 2:74530805-74530805
8 overlap with 4 genes GRCh37/hg19 16p11.2(chr16:29814850-29830976)x4 CN GAIN Uncertain Significance
221514 GRCh37: 16:29814850-29830976
GRCh38:
9 overlap with 4 genes GRCh37/hg19 19p13.2(chr19:7682488-7698319)x3 CN GAIN Uncertain Significance
221540 GRCh37: 19:7682488-7698319
GRCh38:
10 overlap with 4 genes GRCh37/hg19 3p26.1(chr3:4706901-5216065)x3 CN GAIN Uncertain Significance
221431 GRCh37: 3:4706901-5216065
GRCh38:
11 overlap with 8 genes GRCh37/hg19 11q21(chr11:94696615-95528715)x3 CN GAIN Uncertain Significance
221480 GRCh37: 11:94696615-95528715
GRCh38:
12 overlap with 2 genes chr20:61880169-61908597 complex variant COMPLEX Uncertain Significance
221371 GRCh37: 20:61880169-61908597
GRCh38:
13 overlap with 215 genes chr1:909238-16736132 complex variant COMPLEX Uncertain Significance
221357 GRCh37: 1:909238-16736132
GRCh38:
14 overlap with 2 genes GRCh38/hg38 16q22.2(chr16:72059151-72063259)x0 CN LOSS Uncertain Significance
221526 GRCh37: 16:72093050-72097158
GRCh38: 16:72059151-72063259
15 NIPBL GRCh37/hg19 5p13.2(chr5:37000955-37014827)x4 CN GAIN Uncertain Significance
221443 GRCh37: 5:37000955-37014827
GRCh38:
16 overlap with 6 genes GRCh37/hg19 5q12.1(chr5:60240797-61658323)x3 CN GAIN Uncertain Significance
221383 GRCh37: 5:60240797-61658323
GRCh38:
17 overlap with 4 genes GRCh37/hg19 2q31.1(chr2:172379152-172803266)x3 CN GAIN Uncertain Significance
221426 GRCh37: 2:172379152-172803266
GRCh38:
18 overlap with 3 genes GRCh37/hg19 18q12.2(chr18:33611007-33722860)x4 CN GAIN Uncertain Significance
221535 GRCh37: 18:33611007-33722860
GRCh38:
19 overlap with 8 genes GRCh37/hg19 6p22.2-22.1(chr6:26545571-27115102)x3 CN GAIN Uncertain Significance
221452 GRCh37: 6:26545571-27115102
GRCh38:
20 overlap with 19 genes COMPLEX Uncertain Significance
221343 GRCh37: 11:870446-1857751
GRCh38:
21 overlap with 81 genes chr12:10074776-18800953 complex variant COMPLEX Uncertain Significance
221369 GRCh37: 12:10074776-18800953
GRCh38:
22 overlap with 8 genes GRCh37/hg19 16p12.3(chr16:19083339-19586433)x4 CN GAIN Uncertain Significance
221512 GRCh37: 16:19083339-19586433
GRCh38:
23 overlap with 10 genes GRCh37/hg19 12q13.13(chr12:53421635-53645669)x3 CN GAIN Uncertain Significance
221489 GRCh37: 12:53421635-53645669
GRCh38:
24 overlap with 6 genes GRCh37/hg19 2q35(chr2:219221864-219423299)x3 CN GAIN Uncertain Significance
221429 GRCh37: 2:219221864-219423299
GRCh38:
25 overlap with 25 genes chr20:60885242-61929348 complex variant COMPLEX Uncertain Significance
221355 GRCh37: 20:60885242-61929348
GRCh38:
26 overlap with 12 genes GRCh37/hg19 10p11.22-11.21(chr10:32323692-37520394)x3 CN GAIN Uncertain Significance
221475 GRCh37: 10:32323692-37520394
GRCh38:
27 overlap with 6 genes GRCh37/hg19 1p13.2(chr1:113134186-113265713)x3 CN GAIN Uncertain Significance
221415 GRCh37: 1:113134186-113265713
GRCh38:
28 KNDC1 NM_152643.8(KNDC1):c.2914G>T (p.Glu972Ter) SNV Uncertain Significance
221318 rs869025238 GRCh37: 10:135013889-135013889
GRCh38: 10:133200385-133200385
29 overlap with 4 genes GRCh37/hg19 16p11.2(chr16:31123271-31153163)x4 CN GAIN Uncertain Significance
221518 GRCh37: 16:31123271-31153163
GRCh38:
30 overlap with 2 genes GRCh37/hg19 20p12.1(chr20:13714429-13789519)x3 CN GAIN Uncertain Significance
221544 GRCh37: 20:13714429-13789519
GRCh38:
31 overlap with 5 genes GRCh37/hg19 3q26.31(chr3:172003745-172520446)x3 CN GAIN Uncertain Significance
221435 GRCh37: 3:172003745-172520446
GRCh38:
32 overlap with 24 genes chr19:44501518-45322744 complex variant COMPLEX Uncertain Significance
221352 GRCh37: 19:44501518-45322744
GRCh38:
33 overlap with 7 genes GRCh38/hg38 16q12.1(chr16:47497444-48230506)x1 CN LOSS Uncertain Significance
221521 GRCh37: 16:47531355-48264417
GRCh38: 16:47497444-48230506
34 overlap with 6 genes GRCh37/hg19 7q11.23(chr7:73122969-73256410)x3 CN GAIN Uncertain Significance
221461 GRCh37: 7:73122969-73256410
GRCh38:
35 overlap with 3 genes GRCh37/hg19 6p21.33(chr6:30698482-30853003)x3 CN GAIN Uncertain Significance
221455 GRCh37: 6:30698482-30853003
GRCh38:
36 overlap with 27 genes GRCh38/hg38 17p13.1-12(chr17:9701182-11983353)x1 CN LOSS Uncertain Significance
221395 GRCh37: 17:9604499-11886670
GRCh38: 17:9701182-11983353
37 LRAT NM_004744.5(LRAT):c.78T>A (p.Ser26Arg) SNV Uncertain Significance
221315 rs869025235 GRCh37: 4:155665556-155665556
GRCh38: 4:154744404-154744404
38 overlap with 7 genes GRCh37/hg19 19q13.12(chr19:36227660-36250792)x3 CN GAIN Uncertain Significance
221541 GRCh37: 19:36227660-36250792
GRCh38:
39 overlap with 5 genes GRCh37/hg19 11q23.1(chr11:111735939-111784393)x3 CN GAIN Uncertain Significance
221481 GRCh37: 11:111735939-111784393
GRCh38:
40 overlap with 20 genes GRCh37/hg19 19q13.12(chr19:35516999-35990896)x3 CN GAIN Uncertain Significance
221398 GRCh37: 19:35516999-35990896
GRCh38:
41 overlap with 3 genes GRCh37/hg19 22q13.33(chr22:50318056-50437748)x3 CN GAIN Uncertain Significance
221550 GRCh37: 22:50318056-50437748
GRCh38:
42 overlap with 6 genes GRCh37/hg19 8q22.2(chr8:100871620-101253185)x3 CN GAIN Uncertain Significance
221467 GRCh37: 8:100871620-101253185
GRCh38:
43 PHF24 NM_015297.3(PHF24):c.242G>A (p.Arg81Gln) SNV Uncertain Significance
221301 rs374394658 GRCh37: 9:34971537-34971537
GRCh38: 9:34971540-34971540
44 overlap with 6 genes GRCh38/hg38 21q22.3(chr21:45850091-46137287)x1 CN LOSS Uncertain Significance
221407 GRCh37: 21:47270005-47557201
GRCh38: 21:45850091-46137287
45 overlap with 5 genes chr1:16902894-17264939 complex variant COMPLEX Uncertain Significance
221358 GRCh37: 1:16902894-17264939
GRCh38:
46 NTS NM_006183.5(NTS):c.185G>A (p.Cys62Tyr) SNV Uncertain Significance
221327 rs869025243 GRCh37: 12:86272172-86272172
GRCh38: 12:85878394-85878394
47 overlap with 3 genes GRCh37/hg19 2q31.3-32.1(chr2:182756899-183051256)x4 CN GAIN Uncertain Significance
221427 GRCh37: 2:182756899-183051256
GRCh38:
48 MICAL2 NM_001282663.2(MICAL2):c.3131A>G (p.Asp1044Gly) SNV Uncertain Significance
221304 rs869025227 GRCh37: 11:12278507-12278507
GRCh38: 11:12256960-12256960
49 TUBA3E chr2:130949553-130952725 complex variant COMPLEX Uncertain Significance
221361 GRCh37: 2:130949553-130952725
GRCh38:
50 UNC45A and overlap with 1 gene(s) GRCh37/hg19 15q26.1(chr15:91475054-91478581)x3 CN GAIN Uncertain Significance
221504 GRCh37: 15:91475054-91478581
GRCh38:

Cosmic variations for Breast Ductal Carcinoma:

8 (show top 50) (show all 14495)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM103978702 ZSWIM8 breast,NS,carcinoma,ductal carcinoma c.3423G>A p.K1141= 10:73797261-73797261 15
2 COSM143704807 ZSWIM8 breast,NS,carcinoma,ductal carcinoma c.3408G>A p.K1136= 10:73797261-73797261 15
3 COSM143340021 ZSWIM8 breast,NS,carcinoma,ductal carcinoma c.3423G>A p.K1141= 10:73797261-73797261 15
4 COSM143155659 ZSWIM8 breast,NS,carcinoma,ductal carcinoma c.3408G>A p.K1136= 10:73797261-73797261 15
5 COSM141577245 ZSWIM8 breast,NS,carcinoma,ductal carcinoma c.3309G>A p.K1103= 10:73797261-73797261 15
6 COSM88263804 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.1084G>A p.E362K 23:15822877-15822877 15
7 COSM88263027 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.1406C>T p.S469L 23:15823199-15823199 15
8 COSM88262392 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.1312G>T p.G438C 23:15823105-15823105 15
9 COSM88264460 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.267G>C p.K89N 23:15803751-15803751 15
10 COSM88263630 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.989A>G p.H330R 23:15822782-15822782 15
11 COSM90724063 ZNHIT2 breast,NS,carcinoma,ductal carcinoma c.175G>C p.A59P 11:65117479-65117479 15
12 COSM96875678 ZNF830 breast,NS,carcinoma,ductal carcinoma c.136A>G p.N46D 17:34961702-34961702 15
13 COSM101741828 ZNF668 breast,NS,carcinoma,ductal carcinoma c.856G>A p.G286S 16:31062072-31062072 15
14 COSM133260197 ZNF668 breast,NS,carcinoma,ductal carcinoma c.856G>A p.G286S 16:31062072-31062072 15
15 COSM133259918 ZNF668 breast,NS,carcinoma,ductal carcinoma c.196G>A p.A66T 16:31064264-31064264 15
16 COSM101741790 ZNF668 breast,NS,carcinoma,ductal carcinoma c.992C>G p.T331R 16:31061936-31061936 15
17 COSM131594768 ZNF668 breast,NS,carcinoma,ductal carcinoma c.925G>A p.G309S 16:31062072-31062072 15
18 COSM87497387 ZNF668 breast,NS,carcinoma,ductal carcinoma c.196G>A p.A66T 16:31064264-31064264 15
19 COSM87497658 ZNF668 breast,NS,carcinoma,ductal carcinoma c.856G>A p.G286S 16:31062072-31062072 15
20 COSM132355503 ZNF668 breast,NS,carcinoma,ductal carcinoma c.992C>G p.T331R 16:31061936-31061936 15
21 COSM132355522 ZNF668 breast,NS,carcinoma,ductal carcinoma c.856G>A p.G286S 16:31062072-31062072 15
22 COSM131594485 ZNF668 breast,NS,carcinoma,ductal carcinoma c.265G>A p.A89T 16:31064264-31064264 15
23 COSM131594753 ZNF668 breast,NS,carcinoma,ductal carcinoma c.1061C>G p.T354R 16:31061936-31061936 15
24 COSM132355306 ZNF668 breast,NS,carcinoma,ductal carcinoma c.196G>A p.A66T 16:31064264-31064264 15
25 COSM108404990 ZNF668 breast,NS,carcinoma,ductal carcinoma c.265G>A p.A89T 16:31064264-31064264 15
26 COSM101741584 ZNF668 breast,NS,carcinoma,ductal carcinoma c.196G>A p.A66T 16:31064264-31064264 15
27 COSM133260145 ZNF668 breast,NS,carcinoma,ductal carcinoma c.992C>G p.T331R 16:31061936-31061936 15
28 COSM108405155 ZNF668 breast,NS,carcinoma,ductal carcinoma c.1061C>G p.T354R 16:31061936-31061936 15
29 COSM87497622 ZNF668 breast,NS,carcinoma,ductal carcinoma c.992C>G p.T331R 16:31061936-31061936 15
30 COSM108405172 ZNF668 breast,NS,carcinoma,ductal carcinoma c.925G>A p.G309S 16:31062072-31062072 15
31 COSM87511923 ZNF646 breast,NS,carcinoma,ductal carcinoma c.4010A>T p.N1337I 16:31080334-31080334 15
32 COSM101729269 ZNF646 breast,NS,carcinoma,ductal carcinoma c.4010A>T p.N1337I 16:31080334-31080334 15
33 COSM92054903 ZNF644 breast,NS,carcinoma,ductal carcinoma c.23-23043G>C p.? 1:90941197-90941197 15
34 COSM95319541 ZNF644 breast,NS,carcinoma,ductal carcinoma c.157G>C p.E53Q 1:90941197-90941197 15
35 COSM94049964 ZNF644 breast,NS,carcinoma,ductal carcinoma c.23-23043G>C p.? 1:90941197-90941197 15
36 COSM91884936 ZNF644 breast,NS,carcinoma,ductal carcinoma c.157G>C p.E53Q 1:90941197-90941197 15
37 COSM139305666 ZNF569 breast,NS,carcinoma,ductal carcinoma c.157C>G p.Q53E 19:37426309-37426309 15
38 COSM91675445 ZNF569 breast,NS,carcinoma,ductal carcinoma c.85C>G p.Q29E 19:37426309-37426309 15
39 COSM100881762 ZNF569 breast,NS,carcinoma,ductal carcinoma c.85C>G p.Q29E 19:37426309-37426309 15
40 COSM100886533 ZNF569 breast,NS,carcinoma,ductal carcinoma c.-239-11890C>G p.? 19:37426309-37426309 15
41 COSM139323876 ZNF569 breast,NS,carcinoma,ductal carcinoma c.16-11890C>G p.? 19:37426309-37426309 15
42 COSM90464551 ZNF548 breast,NS,carcinoma,ductal carcinoma c.70G>T p.D24Y 19:57397066-57397066 15
43 COSM139958759 ZNF548 breast,NS,carcinoma,ductal carcinoma c.70G>T p.D24Y 19:57397066-57397066 15
44 COSM93683315 ZNF548 breast,NS,carcinoma,ductal carcinoma c.34G>T p.D12Y 19:57397066-57397066 15
45 COSM140877756 ZNF548 breast,NS,carcinoma,ductal carcinoma c.70G>T p.D24Y 19:57397066-57397066 15
46 COSM141497466 ZNF532 breast,NS,carcinoma,ductal carcinoma c.2465C>T p.S822L 18:58934551-58934551 15
47 COSM90396499 ZNF532 breast,NS,carcinoma,ductal carcinoma c.2465C>T p.S822L 18:58934551-58934551 15
48 COSM141373096 ZNF532 breast,NS,carcinoma,ductal carcinoma c.2465C>T p.S822L 18:58934551-58934551 15
49 COSM139185737 ZNF532 breast,NS,carcinoma,ductal carcinoma c.2465C>T p.S822L 18:58934551-58934551 15
50 COSM139904572 ZNF532 breast,NS,carcinoma,ductal carcinoma c.2465C>T p.S822L 18:58934551-58934551 15

Copy number variations for Breast Ductal Carcinoma from CNVD:

6 (show all 33)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 50888 11 119630000 120260000 Deletion Ductal carcinoma
2 57116 11 63100000 76700000 Amplification CCND1 Ductal carcinoma
3 58629 11 68930000 70160000 Gain Ductal carcinoma
4 58724 11 69230000 69780000 Gain Ductal carcinoma
5 59882 11 78860000 79330000 Deletion Ductal carcinoma
6 60225 11 84000000 88080000 Deletion Ductal carcinoma
7 60766 11 91240000 95940000 Deletion Ductal carcinoma
8 66468 12 2966849 2986303 Copy number FOXM1 Ductal carcinoma
9 98103 16 15360000 17700000 Gain Ductal carcinoma
10 99317 16 25030000 27880000 Gain Ductal carcinoma
11 101507 16 40000 40090000 Gain Ductal carcinoma
12 107663 17 16530000 18020000 Deletion Ductal carcinoma
13 109740 17 28800000 35400000 Amplification ERBB2 Ductal carcinoma
14 116392 17 6500000 10700000 Copy number TP53 Ductal carcinoma
15 117043 17 70920000 72340000 Gain Ductal carcinoma
16 126771 19 20810000 63790000 Gain Ductal carcinoma
17 127047 19 23780000 51950000 Gain Ductal carcinoma
18 128079 19 39420000 40350000 Gain Ductal carcinoma
19 131070 19 52760000 63790000 Gain Ductal carcinoma
20 153161 20 34860000 62370000 Gain Ductal carcinoma
21 153748 20 41100000 62435964 Amplification BMP7 Ductal carcinoma
22 166731 3 107740000 107880000 Deletion Ductal carcinoma
23 166830 3 108620000 110660000 Deletion Ductal carcinoma
24 167069 3 112930000 115910000 Deletion Ductal carcinoma
25 179845 3 99790000 104540000 Deletion Ductal carcinoma
26 196641 5 170120000 170210000 Gain Ductal carcinoma
27 196700 5 170690000 172750000 Gain Ductal carcinoma
28 215548 6 77380000 82650000 Deletion Ductal carcinoma
29 231989 8 110000 5150000 Deletion Ductal carcinoma
30 233354 8 124380000 129070000 Gain Ductal carcinoma
31 234986 8 140450000 141700000 Gain Ductal carcinoma
32 238072 8 29700000 38500000 Amplification FGFR1 Ductal carcinoma
33 239766 8 41480000 42480000 Gain Ductal carcinoma

Expression for Breast Ductal Carcinoma

Search GEO for disease gene expression data for Breast Ductal Carcinoma.

Pathways for Breast Ductal Carcinoma

Pathways related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Super pathways Score Top Affiliating Genes
1 13.75 BCL2 CCND1 CDH1 CTNNB1 CTSD EGFR
2
Show member pathways
13.74 BCL2 BRCA1 CCND1 CDH1 CDH3 CTNNB1
3
Show member pathways
13.72 VEGFD TP53 ESR1 ERBB2 EGFR CCND1
4
Show member pathways
13.44 BCL2 CCND1 EGFR ERBB2 PIP TP53
5
Show member pathways
13.33 BCL2 CDH1 CTNNB1 EGFR ERBB2 PIP
6
Show member pathways
13.31 VEGFD ESR1 ERBB2 EGFR CTNNB1 CDH3
7
Show member pathways
13 BCL2 CCND1 CTSD EGFR ESR1 PGR
8
Show member pathways
12.99 VEGFD TP53 EGFR CCND1 BRCA1 BCL2
9 12.84 VEGFD PGR ESR1 ERBB2 EGFR CTSD
10
Show member pathways
12.69 BCL2 CCND1 CDH1 CTNNB1 EGFR ERBB2
11
Show member pathways
12.64 TP53 ESR1 CCND1 BRCA1 BCL2
12
Show member pathways
12.62 TP53 ERBB2 EGFR CTNNB1 BCL2
13 12.58 VEGFD TP53 EGFR CTNNB1 CDH1 CCND1
14 12.54 BRCA1 CCND1 MKI67 RAD54L TP53
15
Show member pathways
12.52 TP53 ERBB2 EGFR CTNNB1 CDH1
16 12.45 TP53 CTNNB1 CDH3 CDH1 CCND1
17
Show member pathways
12.45 TP53 ERBB2 EGFR CTNNB1 BCL2
18
Show member pathways
12.44 ESR1 EGFR CCND1 BCL2
19
Show member pathways
12.42 VEGFD ERBB2 EGFR CTNNB1 CDH1
20
Show member pathways
12.41 TP53 ESR1 ERBB2 CTNNB1 CDH1 CCND1
21
Show member pathways
12.4 PGR ESR1 CCND1 BRCA1
22
Show member pathways
12.35 TFF1 ESR1 ERBB2 EGFR CCND1
23
Show member pathways
12.25 BCL2 BRCA1 CCND1 TP53
24 12.25 VEGFD ERBB2 EGFR CTNNB1 CCND1 BCL2
25
Show member pathways
12.24 TP53 ERBB2 EGFR CCND1 BCL2
26 12.21 TP53 EGFR CTNNB1 CDH1 CCND1
27
Show member pathways
12.19 BRCA1 CCND1 CTNNB1 EGFR ERBB2 ESR1
28
Show member pathways
12.16 ERBB2 EGFR CTNNB1 CCND1
29 12.14 CTNNB1 CDH3 CDH1 BCL2
30
Show member pathways
12.1 PGR ESR1 ERBB2 EGFR
31 12.08 TP53 EGFR CTSD BCL2
32 12.05 TFF1 CTNNB1 CDH3 CDH1
33 12 CCND1 CDH1 CTNNB1 EGFR
34 11.92 TP53 ERBB2 CTNNB1 CCND1 BCL2
35 11.91 TP53 CCND1 BCL2
36
Show member pathways
11.88 EGFR CTNNB1 CCND1
37
Show member pathways
11.87 ESR1 ERBB2 EGFR
38 11.79 KRT8 CCND1 BCL2
39 11.77 CTNNB1 CDH1 CCND1
40 11.77 MKI67 KRT8 CTNNB1
41
Show member pathways
11.76 CCND1 EGFR ESR1
42 11.76 TP53 ESR1 CTNNB1 CCND1
43 11.74 ESR1 EGFR CCND1
44 11.72 ERBB2 EGFR CTNNB1
45 11.72 TP53 ERBB2 EGFR CTNNB1 CCND1
46 11.7 TP53 ERBB2 BRCA1
47 11.7 ERBB2 CCND1 BRCA1 BCL2
48 11.69 CTNNB1 CCND1 BRCA1
49 11.65 BCL2 BRCA1 CCND1 ESR1
50 11.64 TP53 CCND1 BRCA1

GO Terms for Breast Ductal Carcinoma

Cellular components related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.8 TP53 RAD54L ESR1 EGFR CTNNB1 BRCA1
2 catenin complex GO:0016342 9.1 CTNNB1 CDH3 CDH1

Biological processes related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.13 BRCA1 CDH3 CTNNB1 ERBB2 PGR PIP
2 cell-cell adhesion GO:0098609 10.06 EGFR CTNNB1 CDH3 CDH1 BCL2
3 T cell differentiation in thymus GO:0033077 9.99 TP53 CTNNB1 BCL2
4 fibroblast proliferation GO:0048144 9.93 ESR1 TP53 VEGFD
5 negative regulation of reactive oxygen species metabolic process GO:2000378 9.85 TP53 BRCA1 BCL2
6 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.8 TP53 ESR1
7 B cell lineage commitment GO:0002326 9.78 TP53 BCL2
8 response to xenobiotic stimulus GO:0009410 9.77 BCL2 CCND1 CDH1 CDH3 CTNNB1 RAD54L
9 response to UV-A GO:0070141 9.73 EGFR CCND1
10 response to iron ion GO:0010039 9.73 TFF1 CCND1 BCL2
11 hair cycle process GO:0022405 9.71 CTNNB1 CDH3
12 T cell lineage commitment GO:0002360 9.7 TP53 BCL2
13 cellular response to indole-3-methanol GO:0071681 9.63 CTNNB1 CDH1 BRCA1
14 positive regulation of miRNA maturation GO:1903800 9.55 TP53 EGFR
15 cell population proliferation GO:0008283 9.28 TP53 TFF1 MKI67 EGFR CTNNB1 CCND1

Molecular functions related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.2 BCL2 BRCA1 CDH1 EGFR ERBB2 ESR1
2 enzyme binding GO:0019899 9.8 TP53 PGR ESR1 EGFR CTNNB1 CCND1
3 ATP-dependent DNA/DNA annealing activity GO:0036310 9.56 TP53 RAD54L
4 protein phosphatase binding GO:0019903 9.28 TP53 ERBB2 EGFR CTNNB1 BCL2

Sources for Breast Ductal Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....